V5 Ultimate
Ultimate
PricingResourcesCompany
English (original)العربيةDeutschΕλληνικάEspañolFrançaisItalianoעברית日本語한국어NederlandsPolskiPortuguêsSvenska
Talk to us Log in Start free trial
Food & Beverage
  • Bakery & Confectionery
  • Food Processing
  • Ingredients & Dry Mixes
  • Sausage & Meat Products
  • Produce Packing
  • Pet Food & Pet Supplements
  • Dairy & Chilled Foods
  • Beverages & Liquid Manufacturing
  • Infant Formula
Pharma & Life Sciences
  • Radiopharmaceuticals
  • Pharmaceutical
  • Medical Devices
  • Veterinary Pharmaceuticals
  • Blood & Tissue
  • Diagnostics & IVD Kits
  • Reference Materials & Standards
  • OTC Topical Creams & Gels
Supplements & Personal Care
  • Dietary Supplements
  • Cosmetics & Personal Care
  • Cannabis & Hemp Manufacturing
  • Fragrances & Perfumery
  • Soaps & Personal Hygiene
  • Botanical Extracts & Essential Oils
Chemicals & Materials
  • Plastics & Resins
  • Agricultural Chemicals
  • Specialty & Industrial Chemicals
  • Printing Inks, Pigments & Construction Chemicals
  • Lubricants & Metalworking Fluids
  • Coatings, Adhesives & Sealants
Other Manufacturing
  • Consumer Products
  • Electronics & Electrical Assembly
  • Textiles & Nonwoven
  • Contract Manufacturing & Co-Packing
  • Packaging & Food-Contact Materials
  • Regulated Warehousing & Distribution
Explore all industries
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Why V5? Product & Features
Why V5?Product & Features
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Explore all industries
    • Bakery & Confectionery
    • Food Processing
    • Ingredients & Dry Mixes
    • Sausage & Meat Products
    • Produce Packing
    • Pet Food & Pet Supplements
    • Dairy & Chilled Foods
    • Beverages & Liquid Manufacturing
    • Infant Formula
    • Radiopharmaceuticals
    • Pharmaceutical
    • Medical Devices
    • Veterinary Pharmaceuticals
    • Blood & Tissue
    • Diagnostics & IVD Kits
    • Reference Materials & Standards
    • OTC Topical Creams & Gels
    • Dietary Supplements
    • Cosmetics & Personal Care
    • Cannabis & Hemp Manufacturing
    • Fragrances & Perfumery
    • Soaps & Personal Hygiene
    • Botanical Extracts & Essential Oils
    • Plastics & Resins
    • Agricultural Chemicals
    • Specialty & Industrial Chemicals
    • Printing Inks, Pigments & Construction Chemicals
    • Lubricants & Metalworking Fluids
    • Coatings, Adhesives & Sealants
    • Consumer Products
    • Electronics & Electrical Assembly
    • Textiles & Nonwoven
    • Contract Manufacturing & Co-Packing
    • Packaging & Food-Contact Materials
    • Regulated Warehousing & Distribution
PricingResourcesCompany
Start free trial Log in Talk to us
HomeGlossaryUSP General Chapter <800>
Compliance · The complete guide

USP General Chapter <800>USP General Chapter <800> Hazardous Drugs — Handling in Healthcare Settings

In short

USP <800> establishes essential standards for the safe handling of hazardous drugs to protect healthcare personnel, patients, and the environment from the risks of occupational exposure.

2,939 words · ~14 min read
Compounding technician in full PPE handling sealed vials at a biological safety cabinet
Compounding technician in full PPE handling sealed vials at a biological safety cabinet.
On this page
  1. 01Introduction to USP <800> and Hazardous Drug Safety
  2. 02The NIOSH List: Defining Hazardous Drugs (HDs)
  3. 03Facility Engineering Controls: C-PEC and C-SEC
  4. 04Closed System Drug-Transfer Devices (CSTDs)
  5. 05Personal Protective Equipment (PPE) and Double Gloving
  6. 06The Cleaning Continuum: Deactivation to Disinfection
  7. 07Receiving, Storage, and Transport of Hazardous Drugs
  8. 08Spill Management and Emergency Procedures
  9. 09Disposal and Waste Management
  10. 10Personnel Training and Medical Surveillance
  11. 11Integration with USP <795> and USP <797>
  12. 12Operationalizing Safety: SOPs and Governance
On this page · 12 sections
  1. 1Introduction to USP <800> and Hazardous Drug Safety
  2. 2The NIOSH List: Defining Hazardous Drugs (HDs)
  3. 3Facility Engineering Controls: C-PEC and C-SEC
  4. 4Closed System Drug-Transfer Devices (CSTDs)
  5. 5Personal Protective Equipment (PPE) and Double Gloving
  6. 6The Cleaning Continuum: Deactivation to Disinfection
  7. 7Receiving, Storage, and Transport of Hazardous Drugs
  8. 8Spill Management and Emergency Procedures
  9. 9Disposal and Waste Management
  10. 10Personnel Training and Medical Surveillance
  11. 11Integration with USP <795> and USP <797>
  12. 12Operationalizing Safety: SOPs and Governance
AI · Explain it for MY operation

How does USP General Chapter <800> apply to your shop floor?

Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.

Your scale

01Introduction to USP <800> and Hazardous Drug Safety

USP General Chapter <800>, titled 'Hazardous Drugs—Handling in Healthcare Settings,' represents a paradigm shift in occupational safety for the healthcare and pharmaceutical industries. Unlike many quality-focused chapters that prioritize the end-product, USP <800> is primarily concerned with the safety of the personnel who handle hazardous drugs (HDs), the patients who receive them, and the environment in which they are processed. The standard provides a comprehensive framework for the receipt, storage, compounding, dispensing, administration, and disposal of drugs identified as hazardous.

The need for such a standard arises from the inherent risks associated with many modern therapies. Many drugs, particularly those used in oncology, exhibit toxicities that can lead to severe health consequences for workers exposed even to trace amounts. These consequences include reproductive issues, organ damage, and an increased risk of cancer. According to USP, the chapter describes requirements including responsibilities of personnel, facility and engineering controls, and procedures for deactivating and cleaning [1]. It is not merely a recommendation; in many jurisdictions, it is an enforceable standard through state boards of pharmacy or federal agencies like OSHA.

The scope of USP <800> is broad, covering every point in the supply chain where a healthcare worker might come into contact with a hazardous drug. This includes not just the pharmacists and technicians compounding the drugs, but also the nurses administering them, the housekeeping staff cleaning the rooms, and the logistics personnel receiving the shipments. The goal is to create a 'containment-based' approach that assumes any residue is a potential threat and must be managed accordingly.

V5 Ultimate supports USP <800> alignment by providing dedicated workflows for HD inventory, ensuring that hazardous materials are flagged at receiving and tracked through specific containment protocols.

02The NIOSH List: Defining Hazardous Drugs (HDs)

Central to the application of USP <800> is the identification of which drugs are considered hazardous. USP <800> relies on the National Institute for Occupational Safety and Health (NIOSH) to define these criteria. The NIOSH List of Hazardous Drugs in Healthcare Settings is the authoritative source for this classification [3]. NIOSH defines a drug as hazardous if it exhibits one or more of the following characteristics in humans or animals: carcinogenicity, teratogenicity or developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, or a structure and toxicity profile that mimics existing hazardous drugs [1].

The 2024 NIOSH update introduces a more streamlined categorization compared to the 2016 version. It moves away from the three-group system (Antineoplastic, Non-Antineoplastic, and Reproductive-only) toward a more risk-based assessment that aligns with modern drug development. This shift requires facilities to re-evaluate their formularies and ensure that every drug entering the facility is screened against the latest NIOSH criteria.

Assessment of Risk (AoR)

While all drugs on the NIOSH list are technically HDs, USP <800> allows for an Assessment of Risk (AoR) for certain drugs or dosage forms. This is a critical operational flexibility. For example, a facility might perform an AoR for hazardous drugs that are in their final, finished dosage forms—such as coated tablets or capsules—that do not require further manipulation. The AoR allows the facility to implement alternative containment strategies, such as wearing a single pair of gloves rather than the full suite of PPE required for compounding, provided the safety of personnel is maintained through documentation and rigorous work practices.

The AoR must be documented and reviewed at least annually. It must consider the drug type, dosage form, risk of exposure, and the packaging. If a facility chooses not to perform an AoR, they must follow the default containment and PPE requirements for all drugs on the NIOSH list, regardless of the dosage form or activity.

NIOSH CategoryDescriptionHandling Focus
AntineoplasticChemotherapy and related toxinsStrict containment (C-PEC/C-SEC) required.
Non-AntineoplasticDrugs meeting other hazard criteriaMay allow AoR based on dosage form.
Reproductive HazardDrugs posing risks to fertility or fetusesFocus on personnel selection and PPE.

03Facility Engineering Controls: C-PEC and C-SEC

To minimize occupational exposure, USP <800> mandates a 'hierarchy of controls' that starts with the physical environment. Engineering controls are categorized into Primary (C-PEC) and Secondary (C-SEC) containment. The primary goal is to ensure that hazardous vapours, dusts, and residues are captured at the source and prevented from contaminating the wider facility.

Containment Primary Engineering Control (C-PEC)

The C-PEC is the ventilated device designed to minimize worker and environmental exposure when directly handling HDs. For non-sterile hazardous compounding, a Containment Ventilated Enclosure (CVE) or a Class I Biological Safety Cabinet (BSC) may be used. For sterile hazardous compounding, the C-PEC must be a Class II or III BSC or a Compounding Aseptic Containment Isolator (CACI). These devices provide an ISO Class 5 environment for the product while simultaneously protecting the operator through inward airflow and HEPA filtration.

Containment Secondary Engineering Control (C-SEC)

The C-SEC is the room in which the C-PEC is placed. USP <800> requires that the C-SEC be physically separate from other areas, externally exhausted through high-efficiency particulate air (HEPA) filters, and maintained at a negative pressure relative to surrounding areas (typically -0.01 to -0.03 inches of water column). This ensures that any accidental release of HD residue is contained within the room and safely removed through the exhaust system rather than migrating to non-hazardous work zones.

The C-SEC must also meet specific air change requirements. For non-sterile compounding, at least 12 air changes per hour (ACPH) are required. For sterile compounding in an ISO Class 7 buffer room, at least 30 ACPH are required. The exhaust must be directed outside the building, away from any air intake vents, to prevent the re-entry of hazardous particles into the facility.

Never use a positive-pressure laminar airflow workbench (LAFW) or a compounding aseptic isolator (CAI) for hazardous drugs, as these devices blow air toward the operator, significantly increasing exposure risk.

04Closed System Drug-Transfer Devices (CSTDs)

Beyond the C-PEC and C-SEC, USP <800> introduces the concept of Supplemental Engineering Controls, most notably Closed System Drug-Transfer Devices (CSTDs). A CSTD is a device that mechanically prevents the escape of a drug in vapor or liquid form and the entry of environmental contaminants into the system.

USP <800> mandates the use of CSTDs for the administration of antineoplastic HDs when the dosage form allows. Their use during compounding is highly recommended but not strictly required if a C-PEC is used. However, many facilities choose to use CSTDs during both compounding and administration to provide an extra layer of protection. CSTDs are particularly effective at preventing the 'micro-spills' and aerosolization that occur during the priming of IV tubing or the spiking of IV bags.

The selection of a CSTD should be based on independent validation data showing the device's ability to contain vapors and liquids under clinical conditions. As noted by NIOSH, not all devices marketed as 'closed' are equally effective, and facilities must verify the performance of their chosen system [2].

05Personal Protective Equipment (PPE) and Double Gloving

When engineering controls are insufficient or during activities where exposure is possible (like cleaning or spill management), Personal Protective Equipment (PPE) provides the final line of defense. USP <800> specifies rigorous PPE requirements for anyone handling HDs, with a heavy emphasis on the integrity of the materials.

  • Gloves: Personnel must wear two pairs of chemotherapy-rated gloves (ASTM D6978) when compounding, administering, or cleaning HDs. The outer glove should be tucked under the cuff of the gown, and the inner glove should be over the cuff. Gloves must be changed every 30 minutes unless otherwise recommended by the manufacturer.
  • Gowns: Disposable, lint-free, and tested for resistance to HDs. Gowns must close in the back, have long sleeves with elastic or knit cuffs, and be changed every 2 to 3 hours or immediately after a spill.
  • Head/Hair/Shoe Covers: Two pairs of shoe covers are required when entering the C-SEC to prevent the tracking of HD residue out of the containment area. The outer shoe cover is removed before leaving the negative pressure zone.
  • Respiratory Protection: A fit-tested N95 respirator provides protection against particles but not against vapors. If the AoR indicates a risk of vapor exposure, a surgical N95 or a full-face chemical cartridge respirator may be required.

Proper donning and doffing sequences are critical to avoid self-contamination. The outermost layer of PPE is typically considered contaminated and must be removed carefully within the C-SEC or a designated transition area. Hand hygiene must be performed immediately after removing gloves. According to OSHA, failure to follow proper doffing procedures is a common source of secondary exposure for healthcare workers [5].

06The Cleaning Continuum: Deactivation to Disinfection

Cleaning in a hazardous drug environment is a multi-step process that differs significantly from standard pharmacy cleaning. It involves four distinct steps that must be performed in sequence to ensure the environment is safe for both products and personnel.

  1. Deactivation: The first step, which renders the HD compound inactive or less toxic. Common agents include sodium hypochlorite (bleach) or other validated oxidizing agents. This step is critical for breaking down the chemical structure of the drug.
  2. Decontamination: The physical removal of HD residue from surfaces. This is often achieved using the same agents as deactivation, followed by a rinse with water or a detergent to remove the chemical byproduct of the deactivation step.
  3. Cleaning: The removal of organic and inorganic soil (dirt, dust, oils) using a detergent. This ensures that the surface is physically clean before the final step.
  4. Disinfection: The destruction of microorganisms. This is only required for sterile compounding areas and usually involves the application of sterile 70% isopropyl alcohol (IPA) or a validated sporicidal agent.

Decontamination must be performed daily for all work surfaces within the C-PEC and C-SEC. It must also be performed after any spill or if there is reason to suspect contamination. The use of 'wipe testing' or surface sampling for HD residue is recommended by USP <800> to verify the effectiveness of the decontamination process. While no specific 'safe' limit for surface residue has been established by regulators, the goal is to keep levels as low as reasonably achievable (ALARA).

Always verify that your deactivation agents are compatible with the stainless steel and plastics in your C-PEC, as some oxidizing agents can cause pitting and corrosion if not properly rinsed.

07Receiving, Storage, and Transport of Hazardous Drugs

The risk of exposure begins the moment an HD package enters the facility. USP <800> requires specific protocols for receiving and storing HDs to protect staff who may not be part of the compounding team. This includes personnel in the loading dock and the warehouse.

Receiving HDs

HDs should be received in an area that is neutral or negative pressure relative to the surrounding areas. Staff should not open HD shipping containers in positive-pressure areas or near air intakes. Personnel receiving HDs must wear at least one pair of chemotherapy-rated gloves. If a package appears damaged, it must be treated as a spill and moved to a C-PEC for inspection. The manufacturer or wholesaler should be notified of any compromised shipments.

Storage and Inventory Management

HDs must be stored in a manner that prevents breakage or leakage. They must be stored separately from non-HDs in a dedicated room that is externally exhausted and maintained at a negative pressure. Refrigerated HDs must be stored in a dedicated refrigerator located in a negative-pressure area with at least 12 ACPH. Proper signage is required to clearly identify the storage area as containing hazardous drugs.

Transporting HDs within the facility requires the use of sealed, leak-proof, and impact-resistant containers. Labels should clearly identify the contents as hazardous to alert staff in case of an accident. Pneumatic tube systems must never be used to transport liquid HDs or any antineoplastic HDs, as a leak within the tube system could contaminate the entire facility's HVAC or transit network.

08Spill Management and Emergency Procedures

Spills are an inevitable risk in healthcare. USP <800> requires facilities to have a written spill management plan and readily available spill kits in all areas where HDs are handled. The response to a spill must be immediate to prevent the spread of contamination.

A comprehensive spill kit should include all necessary PPE (double gloves, gown, shoe covers, and a respirator), absorbent materials (pads and pillows), deactivation/decontamination agents, and hazardous waste disposal bags. All personnel who handle HDs must be trained in spill response at least annually. Any spill must be documented, and the root cause should be investigated through the facility's CAPA process to prevent recurrence. This documentation is essential for both regulatory compliance and for the facility's medical surveillance program.

"All spills must be contained and cleaned immediately by trained personnel. The circumstances and handling of the spill must be documented, and the personnel involved must be evaluated for exposure."

— USP General Chapter <800>

09Disposal and Waste Management

Disposal of HD waste is governed by both USP <800> and environmental regulations such as the Resource Conservation and Recovery Act (RCRA). Hazardous waste must be segregated into appropriate containers at the point of use. This includes 'trace' waste (such as empty vials and used PPE) and 'bulk' waste (such as expired drugs or partially used IV bags).

Waste containers must be leak-proof, puncture-resistant, and clearly labeled. They should be kept closed when not in use and disposed of through a licensed hazardous waste contractor. Improper disposal not only risks environmental contamination but can also lead to heavy fines from the EPA or state environmental agencies.

10Personnel Training and Medical Surveillance

Human error is a significant contributor to occupational exposure. USP <800> mandates initial and annual training for all personnel who may come into contact with HDs. This training must be documented and should include a physical demonstration of competency, particularly for donning and doffing PPE.

Medical Surveillance Programs

While USP <800> does not strictly mandate a specific medical surveillance program (deferring to institutional policy), it strongly recommends one as part of a comprehensive safety plan. A surveillance program involves monitoring the health of employees who handle HDs to detect early signs of exposure or toxicity. Key components include:

  • Initial Assessment: A baseline physical exam and medical history, including reproductive history, performed before the employee begins handling HDs.
  • Periodic Monitoring: Annual or biennial check-ups to track changes in health status.
  • Post-Exposure Evaluation: Immediate medical assessment following a spill or accidental exposure.
  • Record Keeping: Maintaining confidential medical records for the duration of employment plus 30 years, as required by OSHA.

As noted by NIOSH, surveillance is a critical tool for identifying failures in containment and engineering controls that might otherwise go unnoticed [2].

11Integration with USP <795> and USP <797>

USP <800> does not exist in a vacuum. It works alongside USP <795> (Non-Sterile Compounding) and USP <797> (Sterile Compounding). When a hazardous drug is compounded, the requirements of both the specific compounding chapter and USP <800> must be met. This intersection often creates complex operational requirements.

For example, if a facility is compounding a sterile hazardous drug, it must meet the ISO Class 7 air quality and aseptic technique requirements of USP <797> while simultaneously maintaining the negative pressure and external exhaust requirements of USP <800>. The C-PEC must provide the ISO Class 5 air for the product while the C-SEC provides the negative pressure for the worker. This dual focus ensures that both the product (sterility) and the operator (safety) are protected.

ActivityPrimary ChapterSafety Overlay
Sterile Hazardous CompoundingUSP <797>USP <800> Containment + PPE
Non-Sterile Hazardous CompoundingUSP <795>USP <800> Containment + PPE
HD AdministrationInstitutional SOPsUSP <800> PPE + CSTD
HD ReceivingUSP <800>PPE + Negative Pressure Storage

12Operationalizing Safety: SOPs and Governance

Successful implementation of USP <800> requires a culture of safety supported by robust governance. This starts with the designation of a Compounding Expert or 'Hazardous Drug Officer' who is responsible for overseeing the safety program and ensuring that the facility remains aligned with the latest standards.

Detailed Standard Operating Procedures (SOPs) must be developed for every aspect of HD handling. These SOPs should be reviewed annually and updated as the NIOSH list or facility practices change. Regular auditing and environmental sampling for HD residue can help verify that containment strategies are effective and that staff are following the required protocols.

V5 Ultimate enables digital governance for HD safety by centralizing SOP management and ensuring that training records are systematically linked to operator permissions in the compounding suite.

Frequently asked questions

Q.Does USP <800> apply to drugs that are not on the NIOSH list?+

Technically, USP <800> applies specifically to hazardous drugs, and it points to the NIOSH list as the primary identifier. However, if a facility identifies a new drug that meets the NIOSH criteria for hazardousness—such as a new antineoplastic agent that has not yet been added to the biennial update—it is best practice to handle it according to USP <800> standards to ensure personnel safety.

Q.Can I store hazardous drugs in the same refrigerator as non-hazardous drugs?+

No. USP <800> requires that hazardous drugs be stored in a dedicated refrigerator located in a negative-pressure area. This prevents the risk of cross-contamination that could occur if non-hazardous vials were placed next to HD containers that might have external residue. If a refrigerator is located in a non-negative pressure area, it cannot be used for HD storage.

Q.Is double gloving always required when handling HDs?+

Double gloving is strictly required during compounding, administration, and spill cleanup of all HDs. For other activities such as receiving or transporting sealed, intact containers, a single pair of chemotherapy-rated gloves may be sufficient based on the facility's documented Assessment of Risk (AoR). However, two pairs are generally recommended as a safety buffer whenever there is a potential for contact.

Primary sources

  • USP General Chapter <800>
  • NIOSH List of Hazardous Drugs in Healthcare Settings, 2024
  • OSHA: Controlling Occupational Exposure to Hazardous Drugs
  • CDC/NIOSH: Managing Hazardous Drug Exposures (2023)

Further reading

  • USP <797>
    Understand how sterile compounding standards intersect with hazardous drug containment.
  • Standard Operating Procedures
    The foundation of a robust hazardous drug safety program.
  • CAPA
    Managing deviations and spills through formal corrective and preventive actions.
  • cGMP
    The broader regulatory context for quality and safety in drug handling.
Software that covers USP General Chapter <800>
V5 Ultimate for USP <797> / <800>
The 2023 revision of USP <797> updated requirements for beyond-use dating, environmental monitoring, garbing competencies and…
V5 Ultimate for OSHA PSM
29 CFR 1910.119 puts fourteen management-system elements on the operator of a Highly Hazardous Chemical process — PSI, PHA,…
V5 Ultimate for Annex 1
Sterile and aseptic manufacturing under the revised EU GMP Annex 1 (August 2023 effective) — a live Contamination Control…
V5 Ultimate (Pharmaceutical Manufacturing)
V5 Ultimate is a single-platform MES / QMS / LIMS / WMS for US pharmaceutical manufacturers under 21 CFR 210 and 211.
Talk to us about USP General Chapter <800>

Want to see how USP General Chapter <800> could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.

Start free
Back to glossary
Where this term comes up
PharmaceuticalVet PharmaRadiopharma
Inside V5
  • → Score your compliance gap — then download the validation pack.
  • → Document control — one version in force, every change signed and explained.
  • → Audits whose findings reach an owner.
  • → QMS — quality records next to the work they concern.
Example reports
V5Ultimate

Sample report

CAPA Record

Quality system

CAPA RecordView on screen or print
V5Ultimate

Sample report

Complaint File

Quality system

Complaint FileView on screen or print
→ All example reports
Regulatory anchors
  • USP General Chapter <800>
  • USP General Chapter <795>
  • USP General Chapter <797>
  • 29 CFR 1910.1200
  • NIOSH List of Antineoplastic and Other Hazardous Drugs
Related terms
  • → USP <800>
  • → USP <797>
  • → USP

Next Step

Try V5 with your own records, or ask a question first. Ask V5 opens with an editable question; nothing is sent until you choose to.

Start your free trial Browse All Features

Showing the site for the United States. Local spelling, dates and prices are applied automatically; change the language at the top of the page.

V5 Ultimate
Ultimate

Warehouse, quality and manufacturing software for regulated operations.

ProductIndustriesPricingResourcesSecurity & TrustCompanyLegal Centre

© S.G. Systems, LLC